Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Genmab A/S NASDAQ:GMAB | $31.67B | $51.37 | Not rated | 18.7 | +66.73% |
Incyte Corporation NASDAQ:INCY | $24.66B | $120.97 | Undervalued | 13.7 | +16.27% |
Disc Medicine, Inc. NASDAQ:IRON | $3.07B | $80.00 | Not rated | -11.2 | -14.06% |
Hemab Therapeutics Holdings, Inc. Common Stock NASDAQ:COAG | $1.91B | $40.86 | Not rated | — | — |
uniQure N.V. NASDAQ:QURE | $1.67B | $23.81 | Not rated | -14.1 | -27.37% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | $44.46 | Undervalued | 1.7 | +2.04% |
Geron Corporation NASDAQ:GERN | $622.98M | $0.97 | Not rated | -12.3 | -8.25% |
Keros Therapeutics, Inc. NASDAQ:KROS | $202.13M | $10.30 | Undervalued | -4.6 | -28.83% |
Continue the stock analysis
Jump to another research area for this company.